Since metastatic cancer is a systemic disease, ultimately systemic (blood-borne) therapies must be developed that can reach tumor cells wherever in the body they have spread. The blood-brain-barrier (BBB) poses a formidable challenge to designing such therapies for cancer spread to the CNS. The overall goal of this project will be to develop an effective means of delivering systemically administered drugs to the brain where they would be used to diagnose and/or treat brain malignancies. The therapies must be able both to target across the BBB and once within the brain target the malignant cells. The strategy will be to use the growth factor receptors on the BBB as transport vehicles for gaining access to the brain. In earlier studies, the investigators have shown that both transferrin and antibodies to the transferrin receptor can be used to transport fusion proteins across the BBB. They will use tumor specific antibodies recognizing HER2/neu and would target cell lines expressing HER2/neu that have been injected into the brain. Proteins that they will produce include an anti-TfR-avidin fusion protein which will be used to deliver a biotinylated anti-tumor antibody, an anti-tumor- Tf fusion protein, and a tetra-valent, bispecific molecule with recognition both for the Tar and tumor associated antigens. These initial proteins will not be inherently cytotoxic but would be used to target radioactivity as either a diagnostic or cytotoxic agent to tumors. Proteins will be evaluated in vitro for their size, assembly, stability and ability to bind their respective targets (the Tar or tumor antigen) and in vivo for their pharmacokinetic properties including their transport across the BBB and ability to secondarily target tumors. The investigators will also develop potential therapeutic molecules using the Antibody Directed Enzyme Prodrug Therapy (ADEPT) approach. In this approach, the antibody will be used to target an enzyme to the tumor; the targeted enzyme will then convert a non-toxic prodrug to a toxic agent only at the site of the tumor. Fusion proteins will be constructed using herpes virus thymidine kinase (HSV-TK) with ganciclovir as the prodrug and using cytosine deamidase (CD) with 5-fluorocytosine (5-FC) as the prodrug. These fusion proteins will be evaluated in vitro for enzymatic activity and ability to bind antigen and the TfR and in vivo for their transport across the BBB and ability to target tumors and kill them in the presence of the prodrug.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA087990-01
Application #
6192183
Study Section
Special Emphasis Panel (ZRG1-BDCN-4 (01))
Program Officer
Fu, Yali
Project Start
2000-05-10
Project End
2005-04-30
Budget Start
2000-05-10
Budget End
2001-04-30
Support Year
1
Fiscal Year
2000
Total Cost
$229,050
Indirect Cost
Name
University of California Los Angeles
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
119132785
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Huang, Tzu-Hsuan; Chintalacharuvu, Koteswara R; Morrison, Sherie L (2007) Targeting IFN-alpha to B cell lymphoma by a tumor-specific antibody elicits potent antitumor activities. J Immunol 179:6881-8
Huang, Tzu-Hsuan; Morrison, Sherie L (2006) A trimeric anti-HER2/neu ScFv and tumor necrosis factor-alpha fusion protein induces HER2/neu signaling and facilitates repair of injured epithelia. J Pharmacol Exp Ther 316:983-91
Dela Cruz, Jay Soriano; Trinh, Kamh Ryan; Chen, Hsiao Wen et al. (2006) Anti-HER2/neu IgG3-(IL-2) and anti-HER2/neu IgG3-(GM-CSF) promote HER2/neu processing and presentation by dendritic cells: implications in immunotherapy and vaccination strategies. Mol Immunol 43:667-76
Helguera, Gustavo; Dela Cruz, Jay S; Lowe, Christine et al. (2006) Vaccination with novel combinations of anti-HER2/neu cytokines fusion proteins and soluble protein antigen elicits a protective immune response against HER2/neu expressing tumors. Vaccine 24:304-16
Asai, Tsuneaki; Wims, Letitia A; Morrison, Sherie L (2005) An interaction between S*tag and S*protein derived from human ribonuclease 1 allows site-specific conjugation of an enzyme to an antibody for targeted drug delivery. J Immunol Methods 299:63-76
Dela Cruz, Jay S; Morrison, Sherie L; Penichet, Manuel L (2005) Insights into the mechanism of anti-tumor immunity in mice vaccinated with the human HER2/neu extracellular domain plus anti-HER2/neu IgG3-(IL-2) or anti-HER2/neu IgG3-(GM-CSF) fusion protein. Vaccine 23:4793-803
Asai, Tsuneaki; Trinh, Ryan; Ng, Patrick P et al. (2005) A human biotin acceptor domain allows site-specific conjugation of an enzyme to an antibody-avidin fusion protein for targeted drug delivery. Biomol Eng 21:145-55
Trinh, Ryan; Gurbaxani, Brian; Morrison, Sherie L et al. (2004) Optimization of codon pair use within the (GGGGS)3 linker sequence results in enhanced protein expression. Mol Immunol 40:717-22
Dela Cruz, Jay S; Lau, Suk Ying; Ramirez, Ernesto M et al. (2003) Protein vaccination with the HER2/neu extracellular domain plus anti-HER2/neu antibody-cytokine fusion proteins induces a protective anti-HER2/neu immune response in mice. Vaccine 21:1317-26